Q3 2025 Results
Ipsen’s financial results for the first nine months of 2025 were published on 22 October 2025.
An investor and analyst conference call took place on the same day.
Period
recent search
Showing: 1 – 05 of 26 Financial Results
12 June 2025
Ipsen delivers strong sales in the first quarter 2025 and confirms its full-year guidance
Total sales growth of 11.6% at CER1, or 11.7% as reported, driven by all three therapeutic areas and including an increasing contribution from Iqirvo and Bylvay.Tovorafenib regulatory submission to EMA2 for pediatric low-grade glioma.Confirmation of full-year 2025 financial guidance. PARIS,…
25 July 2024
Ipsen delivers strong results in the first half of 2024, progresses on launches and upgrades its full-year guidance
PARIS, FRANCE, 25 July 2024 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its financial results for the first half of 2024.
24 April 2024
Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidance
PARIS, FRANCE, 24 April 2024 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its sales for the first quarter of 2024.
08 February 2024
Building on solid FY 2023 results, Ipsen anticipates four launches in 2024
PARIS, FRANCE, 8 February 2024 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its financial results for the year and final quarter of 2023.
26 October 2023
Ipsen delivers solid sales growth in the first nine months of 2023 and confirms its full-year guidance
Paris (France), 26 October 2023
Your dedicated contacts
-
Craig Marks
Vice President, Investor Relations
-
-
Nicolas Bogler
Senior Manager, Investor Relations
-